
Eddy Anglade
Eddy has been working in therapeutic development for more than two decades across a range of therapeutic indications and companies, from biotech startups to large pharma. Before joining Octant, Eddy served as a Venture Partner at F-Prime Capital. Previously, as CEO of Tenpoint Therapeutics, he led a transformational merger of a pre-commercial ophthalmology company and built its regenerative ophthalmology strategy. Earlier, he served as Vice President and Clinical Lead for Retina at Janssen Research & Development, where he was late-stage clinical lead for its portfolio of inherited retinal disorders and age-related macular degeneration, and as Vice President and Global Therapeutic Head for Ophthalmology at Astellas, where he championed a first-in-class glaucoma neuroprotection gene therapy now in Phase 1/2 development. He also served as Chief Medical Officer of the Astellas Institute for Regenerative Medicine.
As Chief Medical Officer of Ocata Therapeutics, he led first-in-human trials of human embryonic stem cell-derived retinal pigment epithelial cells in Stargardt macular dystrophy and age-related macular degeneration, culminating in Ocata's $384M acquisition by Astellas. As Co-Founder and Chief Medical Officer of Lux Biosciences, he designed clinical development programs for two orphan-designated, fast-track, first-in-class indications — noninfectious posterior uveitis and high-risk corneal transplantation. Earlier, he held senior clinical development leadership roles at Enzon Pharmaceuticals and Hoffmann-La Roche, following research in retinal immunology and gene transfer at the National Eye Institute.
Eddy earned his M.D. from Yale University School of Medicine, where he was an NIH–Howard Hughes Medical Institute Research Scholar, and his A.B. from Columbia University. He completed his ophthalmology residency at the Massachusetts Eye and Ear Infirmary, Harvard Medical School.
Eddy enjoys spending time with his wife, daughter and extended family, as well as reading, attending theater, museums and live music, and coaching Special Olympics athletes.